The Use of Risk Scores for Thromboprophylaxis in Medically Ill Patients—Rationale and Design of the RICO trial

Abstract

Background Venous thromboembolism (VTE) in hospitalized medically ill patients is a significant cause of morbidity and mortality. Guidelines suggest that VTE and bleeding risk assessment models (RAMs) should be integrated into the clinical decision-making process on thromboprophylaxis. However, poor evidence is available comparing the use of a RAM versus clinical judgement in evaluating VTE and bleeding occurrence.

Methods Reducing Important Clinical Outcomes in hospitalized medical ill patients (RICO) is a multicenter, cluster-randomized, controlled clinical trial (ClinicalTrials.gov Identifier: NCT04267718). Acutely ill patients hospitalized in Internal Medicine wards are randomized to the use of RAMs—namely the Padua Prediction Score and the International Medical Prevention Registry on Venous Thromboembolism Bleeding Score—or to clinical judgement. The primary study outcome is a composite of symptomatic objectively confirmed VTE and major bleeding at 90-day follow-up. Secondary endpoints include the evaluation of clinical outcomes at hospital discharge and the assessment of VTE prophylaxis prescription during the study period. In order to demonstrate a 50% reduction in the primary outcome in the experimental group and assuming an incidence of the primary outcome of 3.5% in the control group at 90-day; 2,844 patients across 32 centers will be included in the study.

Discussion The RICO trial is a randomized study of clinical management assessing the role of RAMs in hospitalized medical ill patients with the aim of reducing VTE and bleeding occurrence. The study has the potential to improve clinical practice since VTE still represents an important cause of morbidity and mortality in this setting.

Keywords

medical patients - venous thromboembolism - RAMs - major bleeding - thromboprophylaxis

Publication History

Received: 19 May 2022

Accepted: 22 August 2022

Accepted Manuscript online:
11 November 2023

Article published online:
12 January 2024

• References

• 1 Gussoni G, Campanini M, Silingardi M. et al; GEMINI Study Group. In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thromb Haemost 2009; 101 (05) 893-901
• 2 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
• 3 Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146 (04) 278-288
• 4 Schünemann HJ, Cushman M, Burnett AE. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018; 2 (22) 3198-3225
• 5 Cave B, Hough A, Dobesh PP. Extended venous thromboembolism prophylaxis in medically ill patients. Pharmacotherapy 2018; 38 (06) 597-609
• 6 Mahan CE, Fisher MD, Mills RM. et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res 2013; 132 (05) 520-526
• 7 Scannapieco G, Ageno W, Airoldi A. et al; TERSICORE Study Group. Incidence and predictors of venous thromboembolism in post-acute care patients. A prospective cohort study. Thromb Haemost 2010; 104 (04) 734-740
• 8 Barbar S, Noventa F, Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8 (11) 2450-2457
• 9 Blondon M, Righini M, Nendaz M. et al. External validation of the simplified Geneva risk assessment model for hospital-associated venous thromboembolism in the Padua cohort. J Thromb Haemost 2020; 18 (03) 676-680
• 10 Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost 2006; 4 (04) 915-916
• 11 Decousus H, Tapson VF, Bergmann JF. et al; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139 (01) 69-79
• 12 Hostler DC, Marx ES, Moores LK. et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. Chest 2016; 149 (02) 372-379
• 13 Kucher N, Koo S, Quiroz R. et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352 (10) 969-977
• 14 Nendaz M, Spirk D, Kucher N. et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost 2014; 111 (03) 531-538
• 15 Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014; 3 (06) e001152
• 16 Rosenberg DJ, Press A, Fishbein J. et al. External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. Thromb Haemost 2016; 116 (03) 530-536
• 17 Spyropoulos AC, Anderson Jr FA, FitzGerald G. et al; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140 (03) 706-714
• 18 Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. J Thromb Haemost 2013; 11 (03) 467-473
• 19 Woller SC, Stevens SM, Jones JP. et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med 2011; 124 (10) 947-954.e2
• 20 Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. J Thromb Haemost 2013; 11 (04) 634-641
• 21 Squizzato A, Agnelli G, Campanini M. et al; FADOI-NoTEVole Study Group. Prophylaxis of venous thromboembolism after hospital discharge in internal medicine: findings from the observational FADOI-NoTEVole study. Thromb Haemost 2019; 119 (12) 2043-2052
• 22 Gibson CM, Chi G, Halaby R. et al; APEX Investigators. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation 2017; 135 (07) 648-655
• 23 Gibson CM, Korjian S, Chi G. et al; APEX Investigators. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX Trial Substudy. J Am Heart Assoc 2017; 6 (07) e006015
• 24 Raskob GE, Spyropoulos AC, Cohen AT. et al. Association between asymptomatic proximal deep vein thrombosis and mortality in acutely ill medical patients. J Am Heart Assoc 2021; 10 (05) e019459
• 25 Spyropoulos AC, Ageno W, Albers GW. et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. J Am Coll Cardiol 2020; 75 (25) 3140-3147
• 26 International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use.. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001; 47 (01) 45-50
• 27 Heo M, Leon AC. Performance of a mixed effects logistic regression model for binary outcomes with unequal cluster size. J Biopharm Stat 2005; 15 (03) 513-526
• 28 Piazza G, Rosenbaum EJ, Pendergast W. et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation 2009; 119 (16) 2196-2201
• 29 Piazza G, Anderson FA, Ortel TL. et al. Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med 2013; 126 (05) 435-442
• 30 Lecumberri R, Marqués M, Díaz-Navarlaz MT. et al. Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. Thromb Haemost 2008; 100 (04) 699-704
• 31 Baroletti S, Munz K, Sonis J. et al. Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. J Thromb Thrombolysis 2008; 25 (02) 146-150
• 32 Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007; 13 (06) 475-486
• 33 Tatar M, Senturk A, Tuna E. et al. Local cost study of treatment of venous thromboembolism in Turkey. Value Health 2015; 18 (07) A388-A389
• 34 Mahan CE, Liu Y, Turpie AG. et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014; 112 (04) 692-699
• 35 Greene MT, Spyropoulos AC, Chopra V. et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med 2016; 129 (09) 1001.e9-1001.e18